Mycoplasma pneumoniae is a leading cause of community-acquired pneumonia in children, and its pathogenesis is fundamentally linked to an excessive host inflammatory response rather than direct bacterial toxicity (
32). A key driver of this immunopathology is activation of the NLRP3 inflammasome, which triggers pyroptosis, a highly inflammatory form of programmed cell death, and the release of potent proinflammatory cytokines (
33). Our study provides novel evidence that AG, a natural diterpenoid lactone, confers significant protection against Mp-induced pneumonia by targeting the HMGB1/TLR4/NF-κB signaling axis, thereby suppressing NLRP3 inflammasome-mediated pyroptosis and the subsequent cytokine storm.
The pivotal role of the NLRP3 inflammasome in Mp infection has been previously established. Segovia et al. demonstrated that Mp and its CARDS toxin activate the NLRP3/ASC/caspase-1 inflammasome complex in macrophages, which is essential for IL-1β processing and secretion, as well as for an effective innate immune response and bacterial clearance in mice (
35). Our findings align with this concept, confirming that Mp infection significantly upregulates NLRP3 expression both in cultured alveolar epithelial cells and in lung tissue. More importantly, we extend this understanding by identifying upstream regulators, namely the DAMP molecule HMGB1 and its receptor TLR4. Extracellular HMGB1, a classic DAMP released during cell stress or necrosis, acts as a late mediator of inflammation (
35). Its interaction with TLR4 initiates a MyD88-dependent signaling cascade leading to activation of the transcription factor NF-κB, which in turn promotes the expression of NLRP3 and pro-IL-1β (
36). Our data clearly demonstrate that Mp infection triggers HMGB1 release and upregulates TLR4 expression, resulting in NF-κB activation. Andrographolide treatment effectively interrupts this upstream signaling, leading to downregulation of NLRP3 expression. This mechanism is strongly supported by recent studies in various disease models. For instance, in acetaminophen-induced hepatotoxicity, scopolin was shown to exert protective effects by concurrently modulating the Nrf2 antioxidant pathway and inhibiting the HMGB1/TLR4/NF-κB/NLRP3 axis (
37). Similarly, tetramethylpyrazine alleviated LPS-induced acute lung injury by specifically inhibiting the HMGB1/TLR4/NF-κB pathway (
38). Most notably, in the context of ischemia/reperfusion injury, panaxynol directly improved cardiac function by inhibiting NLRP3-induced pyroptosis and apoptosis via the HMGB1/TLR4/NF-κB axis (
39). Our study is the first to integrate this mechanistic framework into the context of Mp pneumonia. We demonstrate that AG, by targeting the HMGB1/TLR4/NF-κB axis, effectively suppresses subsequent NLRP3 activation and pyroptosis in alveolar epithelial cells, the primary target cells in Mp infection. This effect was consistent across all our models, as evidenced by reduced LDH release and decreased cleaved caspase-1 expression in vitro, alongside significant amelioration of lung histopathology and decreased levels of the inflammatory cytokines IL-1β, TNF-α, and IL-6 in vivo.
The innovation of our work lies in systematically delineating the complete signaling pathway during the Mp pathological process, from the initial release of HMGB1 to recognition by TLR4, subsequent activation of NF-κB, activation of the NLRP3 inflammasome, and the terminal process of inflammatory cell death, namely pyroptosis, while demonstrating that AG acts across the entire pathway. This offers a therapeutic strategy that is more comprehensive and mechanistically grounded than approaches targeting single downstream components. Despite these compelling findings, certain limitations must be acknowledged. The direct molecular targets of AG within this pathway remain to be precisely identified. Furthermore, the potential synergistic effect of AG combined with conventional macrolide antibiotics against Mp was not explored in this study. Future investigations using tissue-specific knockout models and exploring combination therapies will be valuable for validating this mechanism and advancing AG toward potential clinical application.